Maximilian Ebert
Executive Director, Computational Molecular Sciences Congruence Therapeutics
Maximilian Ebert, PhD is Executive Director of Computational Chemistry at Congruence Therapeutics, where he leads the development of AI- and physics-based drug discovery platforms. His work integrates molecular dynamics, explainable machine learning, and generative design to accelerate small-molecule discovery. Max earned his PhD in Biochemistry from the University of Montreal, focusing on enzyme design, and did his Master’s in Process Engineering at the University of Dortmund and Kyoto University. Before joining Congruence, he advanced molecular modeling innovation at Chemical Computing Group, contributing to the MOE platform.
Seminars
Friday 20th March 2026
Multi-Parameter Optimization Guided by Explainable AI (Xai), Generative Chemistry & Physics-Based Ensemble Modeling: Shortening the Path from Hit-to-Lead Using Revenir
2:00 pm
- Uncover how the Revenir drug discovery platform integrates molecular dynamics, ensemble pocket discovery, and collects AI-driven analytics to accelerate structure function understanding
- Using two case studies to demonstrate how an explainable ML framework identifies atomic drivers of potency and liabilities to guide medicinal chemistry optimization
- Explore how generative design powered by Revenir data enables the rapid discovery of novel, experimentally validated small molecules
